Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 8;7(9-10):68-69.
doi: 10.18632/oncoscience.514. eCollection 2020 Sep.

Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer

Emily M Webster  1 , Burak Zeybek  1 , Joan Tymon-Rosario  1 , Alessandro D Santin  1
Affiliations

Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer

Emily M Webster et al. Oncoscience. .
No abstract available

Keywords: Sacituzumab govitecan; antibody-drug conjugate; endometrial cancer.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no potential conflicts of interest.

Similar articles

See all similar articles

Cited by

  • The Prognostic Role and Significance of Dll4 and Toll-like Receptors in Cancer Development.
    Fasoulakis Z, Koutras A, Ntounis T, Pergialiotis V, Chionis A, Katrachouras A, Palios VC, Symeonidis P, Valsamaki A, Syllaios A, Diakosavvas M, Angelou K, Samara AA, Pagkalos A, Theodora M, Schizas D, Kontomanolis EN. Fasoulakis Z, et al. Cancers (Basel). 2022 Mar 24;14(7):1649. doi: 10.3390/cancers14071649. Cancers (Basel). 2022. PMID: 35406423 Free PMC article. Review.
  • Uterine serous carcinoma.
    Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Nout RA, Lorusso D, Vaughan MM, Bini M, Takano M, Provencher D, Indini A, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Candido Dos Reis FJ, Lopez S, Mariani A, Leitao MM Jr, Raspagliesi F, Panici PB, Di Donato V, Muzii L, Colombo N, Scambia G, Pignata S, Monk BJ. Bogani G, et al. Gynecol Oncol. 2021 Jul;162(1):226-234. doi: 10.1016/j.ygyno.2021.04.029. Epub 2021 Apr 30. Gynecol Oncol. 2021. PMID: 33934848 Free PMC article. Review.

References

    1. Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International Patterns and Trends in Endometrial Cancer Incidence, 1978-2013. J Natl Cancer Inst. 2018;110:354–61. doi: 10.1093/jnci/djx214. - DOI - PubMed
    1. Deleon MC, Ammakkanavar NR, Matei D. Adjuvant therapy for endometrial cancer. J Gynecol Oncol. 2014;25:136–47. doi: 10.3802/jgo.2014.25.2.136. - DOI - PMC - PubMed
    1. Lewin SN, Herzog TJ, Barrena Medel NI, Deutsch I, Burke WM, Sun X, Wright JD. Comparative performance of the 2009 international Federation of gynecology and obstetrics’ staging system for uterine corpus cancer. Obstet Gynecol. 2010;116:1141–49. doi: 10.1097/AOG.0b013e3181f39849. - DOI - PubMed
    1. Onstad M, Ducie J, Fellman BM, Abu-Rustum NR, Leitao M, Mariani A, Multinu F, Lu KH, Soliman P. Adjuvant therapy for grade 3, deeply invasive endometrioid adenocarcinoma of the uterus. Int J Gynecol Cancer. 2020;30:485–90. doi: 10.1136/ijgc-2019-000807. - DOI - PMC - PubMed
    1. Uterine Cancer Version 1.2020 [Accessed April 12 2020];National Comprehensive Cancer Network. 2020 https://www.nccn.org/professionals/physician_gls/pdf/uterine_blocks.pdf

LinkOut - more resources